|Bid||117.00 x 900|
|Ask||126.30 x 800|
|Day's Range||120.20 - 133.85|
|52 Week Range||13.09 - 154.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||168.67|
CONSHOHOCKEN, Pa., May 08, 2018-- Madrigal Pharmaceuticals, Inc. today announced its first quarter 2018 financial results. During the first quarter, the Company also:. Reported that MGL-3196 demonstrated ...
In want of an approved product in Madrigal's (MDGL) portfolio, investors' entire focus on first-quarter earnings call to revolve around the company's lead pipeline candidate, MGL-3196.
One big deal -- and two small ones -- Pfizer could make instead of buying Bristol-Myers Squibb.
Stock Monitor: Madrigal Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors.com has just released a free research report on BeiGene, Ltd (NASDAQ: BGNE ). If you want ...
Stock Monitor: Madrigal Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on Therapix Biosciences Ltd (NASDAQ: TRPX ...
NEW YORK, April 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ), a clinical-stage biotechnology company, could spring a surprise in the non-alcoholic steatohepatitis, or NASH, space, according to Goldman Sachs. The Analyst ...
Madrigal Pharmaceuticals (MDGL) was a big mover last session, as the company saw its shares rise more than 6% on the day.
-MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor β- selective agonist that is being developed for patients with non-alcoholic steatohepatitis and heterozygous familial ...
Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) was a big mover at the end of this week as the company put out its fourth-quarter 2017 financials. The numbers aren’t really what’s driving action however. Instead, the real focus of the markets right now is on a development pipeline update related to one of the company’s lead investigative […] The post Here’s What’s Moving Teva Pharmaceutical Industries And Madrigal Pharmaceuticals appeared first on Market Exclusive.
LONDON, UK / ACCESSWIRE / February 01, 2018 / Active-Investors.com has just released a free research report on Madrigal Pharma, Inc. (NASDAQ: MDGL ). If you want access to this report all you need to do ...
The Zacks Analyst Blog Highlights: Madrigal Pharmaceuticals, Boot Barn Holdings, Famous Dave's of America, CVR Refining and eGain
Sweeping tax cuts, uptick in wages, more confident consumers and an economy on track for the longest expansion in decades will help the market post sizeable returns this year as well.